Skip to main content

Table 3 Absolute or relative VE of bivalent vaccines according to interval since bivalent dose

From: Bivalent mRNA vaccine effectiveness against COVID-19 among older adults in Japan: a test-negative study from the VENUS study

 

n (col. %)

Absolute VEa, % (95% CI)

Relative VEa, % (95% CI)

Vaccination status

 Unvaccinated

1,107 (5.5)

Ref

—

 ≥ 2 monovalent doses

15,189 (76.0)

18.7 (4.8, 30.7)

Ref

 ≤ 13 days since bivalent dose

905 (4.5)

19.2 (-0.6, 35.1)

0.6 (-17.2, 15.7)

 14–20 days since bivalent dose

804 (4.0)

40.3 (24.4, 52.8)

26.5 (11.5, 39.0)

 21–34 days since bivalent dose

1,120 (5.6)

37.8 (22.7, 49.9)

23.4 (10.0, 34.9)

 ≥ 35 days since bivalent dose

873 (4.4)

36.4 (19.8, 49.5)

21.7 (6.1, 34.7)

  1. Analyzed test results were from 17,080 participants (age: 80.9 ± 7.7 years [mean ± standard deviation], 42.3% male). Logistic regression analyses with cluster robust standard errors at the individual level were conducted to estimate the ORs and 95% CIs for testing positive according to the vaccination status. VE was defined as (1 − OR) × 100%
  2. Abbreviations: VE vaccine effectiveness, CI confidence interval, OR odds ratio
  3. aAdjusted for sex, age group, number of comorbidities, infection history, residential municipality, and test week
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us